Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TVTX News 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78. (Business Wire) The timing cuts deep, given this was a straightforward, immediate trigger for Ligand’s royalty setup. Traders
13 January 2026
·····
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

New York, January 13, 2026, 14:17 (EST) — Regular session Shares of Travere Therapeutics (TVTX.O) dropped 19% to $27.56 in early afternoon trading Tuesday after the U.S. Food and Drug Administration extended its review of the kidney drug Filspari for broader use. The stock had fallen as much as 34% earlier, hitting a low of $22.35. (Reuters) The delay comes during a week investors saw as crucial for the small-cap drugmaker’s regulatory path. Winning an expanded label for focal segmental glomerulosclerosis (FSGS) would unlock a fresh market, beyond the drug’s existing approval for IgA nephropathy. Traders had pegged this decision
13 January 2026
····
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

New York, January 6, 2026, 15:27 (ET) — Regular session Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari (sparsentan) into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC The case matters for Travere because FSGS is a rare disease that scars the kidney’s filtering units and can progress to kidney failure. An added label would broaden
6 January 2026
·····
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

NEW YORK, December 30, 2025, 15:16 ET — Regular session Travere Therapeutics Inc shares were down about 3.8% at $37.39 on Tuesday afternoon, extending losses after recent insider-trading disclosures. The stock traded between $37.27 and $39.20, with about 893,000 shares changing hands. (TVTX quote) The selling matters because it lands just weeks before a major regulatory milestone for the rare-disease drugmaker. Traders often react to clusters of insider sales — even when they are planned — as they reassess near-term positioning. Travere, based in San Diego, markets Filspari for a kidney disease called IgA nephropathy, and is seeking an expansion
30 December 2025
·····
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

Vera Therapeutics stock drops 3% today as biotech slips into year-end trading

NEW YORK, December 30, 2025, 2:26 PM ET — Regular session Vera Therapeutics, Inc. shares slid 3.4% to $50.45 in afternoon trading on Tuesday, giving back some recent gains as biotech stocks softened late in the year. The move matters now because Vera has become a bellwether “event-driven” biotech name, where day-to-day trading can swing sharply as investors calibrate risk around FDA timelines and competitive positioning in kidney disease. Thin year-end liquidity can amplify those swings, and traders have been quick to trim exposure to smaller, higher-beta healthcare names when the sector loses momentum. Minutes from the Federal Reserve’s December
30 December 2025
······
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. markets are in pre‑market and set to reopen for the regular session at 9:30 a.m. ET. Travere Therapeutics, Inc. (NASDAQ: TVTX) is entering the post‑holiday session with fresh momentum and a very specific catalyst on investors’ minds: an FDA decision deadline of January 13, 2026 for expanding FILSPARI (sparsentan) into focal segmental glomerulosclerosis (FSGS)—a high‑stakes regulatory event that can move a biotech stock in either direction. Travere Therapeutics TVTX stock: where it stands heading into today’s open TVTX’s most recent regular-session close (Christmas Eve, Dec. 24)
26 December 2025
····
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI (sparsentan) and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2 TVTX stock action on Dec. 24, 2025: a thin-session breakout with big numbers In early trading on Dec. 24, TVTX was up roughly 15% and changing hands around the low $40 range—an outsized move for a single session,
24 December 2025
·····

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Binance scoops up 3,600 more Bitcoin for SAFU as BTC whipsaws after brutal selloff

Binance scoops up 3,600 more Bitcoin for SAFU as BTC whipsaws after brutal selloff

7 February 2026
Binance bought 3,600 bitcoin for its Secure Asset Fund, bringing its holdings to 6,230 BTC after bitcoin rebounded above $70,000 following a sharp drop. The broader crypto market lost about $2 trillion since October, with $1 billion in leveraged bitcoin positions liquidated in 24 hours. Strategy reported a wider Q4 loss as bitcoin fell. Gemini will cut up to 200 jobs and exit the UK, EU, and Australia.
Go toTop